103 related articles for article (PubMed ID: 10437159)
1. Molecular modeling on kappa opioid receptor and its interaction with nonpeptide kappa opioid agonists.
Liu DX; Jiang HL; Shen JS; Zhu WL; Zhao L; Chen KX; Ji RY
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):131-6. PubMed ID: 10437159
[TBL] [Abstract][Full Text] [Related]
2. Establishment of kappa opioid receptor agonists pharmacophore with molecular modeling method.
Liu DX; Tang Y; Jiang HL; Chen KX; Ji RY
Zhongguo Yao Li Xue Bao; 1998 Sep; 19(5):445-50. PubMed ID: 10375807
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling of mu opioid receptor and receptor-ligand interaction.
Rong SB; Zhu YC; Jiang HL; Zhao SR; Wang QM; Chi ZQ; Chen KX; Ji RY
Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):317-22. PubMed ID: 10072913
[TBL] [Abstract][Full Text] [Related]
4. Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists.
Chen Y; Chen C; Wang Y; Liu-Chen LY
J Pharmacol Exp Ther; 2006 Nov; 319(2):765-75. PubMed ID: 16882876
[TBL] [Abstract][Full Text] [Related]
5. Building 3D-structural model of kappa opioid receptor and studying its interaction mechanism with dynorphin A(1-8).
Wan XH; Huang XQ; Zhou DH; Jiang HL; Chen KX; Chi ZQ
Acta Pharmacol Sin; 2000 Aug; 21(8):701-8. PubMed ID: 11501178
[TBL] [Abstract][Full Text] [Related]
6. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
Subramanian G; Paterlini MG; Larson DL; Portoghese PS; Ferguson DM
J Med Chem; 1998 Nov; 41(24):4777-89. PubMed ID: 9822548
[TBL] [Abstract][Full Text] [Related]
7. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
Shenderovich MD; Liao S; Qian X; Hruby VJ
Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling of mu opioid receptor and its interaction with ohmefentanyl.
Tang Y; Chen KX; Jiang HL; Wang ZX; Ji RY; Chi ZQ
Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):156-60. PubMed ID: 9772668
[TBL] [Abstract][Full Text] [Related]
9. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations.
Lavecchia A; Greco G; Novellino E; Vittorio F; Ronsisvalle G
J Med Chem; 2000 Jun; 43(11):2124-34. PubMed ID: 10841791
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of interaction between delta opioid receptor and 3-methylfentanylisothiocyanate.
Rong SB; Jiang HL; Chi ZQ; Chen KX; Zhu YC; Ji RY
Zhongguo Yao Li Xue Bao; 1997 May; 18(3):219-24. PubMed ID: 10072937
[TBL] [Abstract][Full Text] [Related]
11. The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons.
Su X; Castle NA; Antonio B; Roeloffs R; Thomas JB; Krafte DS; Chapman ML
Anesth Analg; 2009 Aug; 109(2):632-40. PubMed ID: 19608841
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
[TBL] [Abstract][Full Text] [Related]
13. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
14. Nonopioid actions of U50,488 enantiomers contribute to their peripheral cutaneous antinociceptive effects.
Joshi SK; Gebhart GF
J Pharmacol Exp Ther; 2003 Jun; 305(3):919-24. PubMed ID: 12626643
[TBL] [Abstract][Full Text] [Related]
15. U-50,488 and the kappa receptor. Part II: 1991-1998.
Szmuszkovicz J
Prog Drug Res; 1999; 53():1-51. PubMed ID: 10616295
[TBL] [Abstract][Full Text] [Related]
16. Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists.
Singh N; Nolan TL; McCurdy CR
J Mol Graph Model; 2008 Sep; 27(2):131-9. PubMed ID: 18456526
[TBL] [Abstract][Full Text] [Related]
17. [Specificity of the anti-arrhythmic effect of kappa1-opioid receptor agonists].
Ugdyzhekova DS; Maslov LN; Krylatov AV; Lishmanov IuB; Tam SV
Eksp Klin Farmakol; 2001; 64(4):17-20. PubMed ID: 11589101
[TBL] [Abstract][Full Text] [Related]
18. Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.
Zhang J; Liu G; Tang Y
J Mol Model; 2009 Sep; 15(9):1027-41. PubMed ID: 19205759
[TBL] [Abstract][Full Text] [Related]
19. Analysis of binding domain and function of chimeric mu/kappa opioid receptors to ohmefentanyl stereoisomers.
Feng YP; Chen LW; Zhou DH; Chen J; Xu XJ; Chi ZQ
Acta Pharmacol Sin; 2001 Nov; 22(11):981-5. PubMed ID: 11749787
[TBL] [Abstract][Full Text] [Related]
20. Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice.
Urigüen L; Berrendero F; Ledent C; Maldonado R; Manzanares J
Eur J Neurosci; 2005 Oct; 22(8):2106-10. PubMed ID: 16262648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
